However, their antiviral applications remain unexplored (Hassannia et al., 2019
On October 22, 2024, Novo Nordisk submitted a nomination to the FDA, arguing that semaglutide products belong on the Demonstrable Difficulties for Compounding (DDC) list due to the complexities associated with their formulations, delivery mechanisms, dosage forms, achievement of bioavailability, compounding processes, and physicochemical and analytical testing. The FDA has yet to make a final decision on whether to ban compounded versions of semaglutide
The timeline for new or complex drugs or biologics could extend to 5 to 7 or more years due to clinical trials and more rigorous regulatory pathways
It is often described as the shortest synthetic peptide with full biological activity of GHRH. Compared with CJC-1295 with DAC, Sermorelin is shorter acting and closer to the original GHRH(1-29) research framework
Mounjaro costs about $6 more per month than Zepbound
Bodmer M, Becker C, Meier C, Jick SS, Meier CR